

Message

---

**From:** Freeman, James J [james.j.freeman@exxonmobil.com]  
**Sent:** 7/31/2015 3:37:08 PM  
**To:** Thomas Hartung [thartun1@jhu.edu]; mandersen@thehamner.org; tara.bartonmaclaren@hc-sc.gc.ca [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c425d09ee9e6481bb6635585f3b16ead-tara.bartonmaclaren@hc-sc.gc.ca]; rbascom@psu.edu; Kim\_boekelheide@brown.edu; Leon Bruner [LBruner@gmaonline.org]; Warren.casey@nih.gov; rcurrent@iivs.org; Dix, David [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c8006c73e3d34ba4af6bf16c1e85fda7-Dix, David]; membry@ilsil.org; Suzanne.Fitzpatrick@fda.hhs.gov; Dianne.garnes@novartis.com; agasp001@umaryland.edu; mglidden@societyforscience.org; thartung@jhsph.edu; awallacehayes@comcast.net; eric.hutchinson@nih.gov; drjuberg@dow.com; aklingenstein@gmail.com; dkrewski@uottawa.ca [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ef67228b71b04e6eb857fc18e459b5bf-dkrewski@uo]; mary\_mcbride@agilent.com; naciff.jm@pg.com; motieno@its.jnj.com; Bernard.robair@mcgill.ca; nrrose@jhsph.edu; arowan@humanesociety.org; Thomas.singer@roche.com; psivac@ifraorg.org; nigel\_skinner@agilent.com; David.steup@shell.com; Tennekoon@email.chop.edu; Thomas, Russell [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=12f119e7a3ee447499f3d6ab5d20daeb-Thomas, Rus]; eve@bernicebarbour.org; scooksey@gmaonline.org; mvey@ifraorg.org; Carl.westmoreland@unilever.com; dwilcox@rifm.org; Jim Yager [jyager1@jhu.edu]; nalepee@rd.loreal.com; sonja.v-aulock@uni-konstanz.de; b.blaauboer@uu.nl; karin.blumer@novartis.com; alexander.buerkle@uni-konstanz.de; francesca.caloni@unimi.it; Mardas.daneshian@uni-konstanz.de; ulrich.deschl@boehringer-ingenheim.com; daniel.dietrich@uni-konstanz.de; fpg@altex.ch; jaworska.j@pg.com [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0ea82ca5d8a44f18b6c9a7e6616aba8f-jaworska.j@pg.com]; liek@sund.ku.dk; harald.krug@empa.ch; Marcel.leist@uni-konstanz.de; manfred.liebsch@gmx.de; f.ohl@uu.nl; walter.pfaller@gmail.com; roman.kolar@tierschutzakademie.de; Donald.Prater@fda.hhs.gov; k.reid@eurogroupforanimals.org; wriedel@bioservice.com; michael.schwarz@uni-tuebingen.de; tseidle@hsi.org; Thomas.singer@roche.com; andrea.seiler@bfr.bund.de; nigel\_skinner@agilent.com; bennard.ravenzwaay@basf.com; Horst.Wenck@Beiersdorf.com; Martin.winter@cetics-ht.com; raija.bettauer [raija.bettauer@verizon.net]  
**Subject:** RE: CAAT Evaluation

Dear CAAT Board: as Director of the Board, I feel compelled to follow-up to Thomas' note to you. For those of you at the retreat in Raleigh this past May, you may recall that Thomas communicated that the self-study was commencing. Since then, you should know that I was interviewed by the Study Team. I shared with the study team verbally (not in writing) the output from February board meeting in D.C. (at which CAAT staff was not present) which was intended to represent a view from the Board. I also suggested to Thomas that he may want to share the written results from that meeting with the study team as one representation of the Board views, and I am sure that he has shared the results of the retreat. With that, the study team has some general input. You are of course welcome to supplement that information as you deem appropriate.

Regards, Jim

**James J. Freeman**  
Distinguished Toxicology Associate

**ExxonMobil Biomedical Sciences, Inc.**  
1545 Route 22 East  
Annandale, New Jersey 08801-3059  
908 730 1123 Tel  
908 730 1199 Fax

The information transmitted in this message is intended only for the person(s) to which it is addressed and may contain confidential information. If you receive this message in error, please delete this message and contact the sender immediately.

ED\_002863\_00000113-00001

---

**From:** Thomas Hartung [mailto:thartun1@jhu.edu]

**Sent:** Thursday, July 30, 2015 9:24 AM

**To:** mandersen@thehamner.org; tara.bartonmaclaren@hc-sc.gc.ca; rbascom@psu.edu; Kim\_boekelheide@brown.edu; Leon Bruner; Warren.casey@nih.gov; rcurren@iivs.org; dix.david@epa.gov; membry@ilsi.org; Suzanne.Fitzpatrick@fda.hhs.gov; Dianne.garnes@novartis.com; Freeman, James J; agasp001@umaryland.edu; mglidden@societyforscience.org; thartung@jhsph.edu; awallacehayes@comcast.net; eric.hutchinson@nih.gov; drjuberg@dow.com; aklingenstein@gmail.com; dkrewski@uottawa.ca; mary\_mcbride@agilent.com; naciff.jm@pg.com; motieno@its.jnj.com; Bernard.robair@mcgill.ca; nrrose@jhsph.edu; arowan@humanesociety.org; Thomas.singer@roche.com; psivac@ifraorg.org; nigel\_skinner@agilent.com; David.steup@shell.com; Tennekoon@email.chop.edu; Thomas.Russell@epa.gov; eve@bernicebarbour.org; scooksey@gmaonline.org; mvey@ifraorg.org; Carl.westmoreland@unilever.com; dwilcox@rilm.org; Jim Yager; nalepee@rd.loreal.com; sonja.v-aulock@uni-konstanz.de; b.blaauboer@uu.nl; karin.blumer@novartis.com; alexander.buerkle@uni-konstanz.de; francesca.caloni@unimi.it; Mardas.daneshian@uni-konstanz.de; ulrich.deschl@boehringer-ingenheim.com; daniel.dietrich@uni-konstanz.de; fpg@altex.ch; jaworska.j@pg.com; liek@sund.ku.dk; harald.krug@empa.ch; Marcel.leist@uni-konstanz.de; manfred.liebsch@gmx.de; f.ohl@uu.nl; walter.pfaller@gmail.com; roman.kolar@tierschutzakademie.de; Donald.Prater@fda.hhs.gov; k.reid@eurogroupforanimals.org; wriedel@bioservice.com; michael.schwarz@uni-tuebingen.de; tseidle@hsi.org; Thomas.singer@roche.com; andrea.seiler@bfr.bund.de; nigel\_skinner@agilent.com; bennard.ravenzwaay@basf.com; Horst.Wenck@Beiersdorf.com; Martin.winter@cetics-ht.com; raija bettauer

**Subject:** CAAT Evaluation

**Importance:** High

Dear CAAT board members, supporters and friends,

As you will know from our financial reports, about 60% of the CAAT budget (beside the research funds) comes from an anonymous donor. The request for a self-study, which we received from our Dean during the board retreat, comes from there, in order to determine our future support.

I have been working with a committee of five distinguished faculty members on this, who also carried out a number of interviews, using a lot of the materials from our self-evaluation.

I now would like to ask your help. To the extent you feel comfortable, could you please appraise with short statements, how you perceive the role and work of CAAT under my leadership and the new directions we are taking?

I would like to provide this to the committee for possible inclusion in the report. This could have enormous impact for the continuing support of CAAT. May I ask you to send such statements within the next two weeks? Your help is really appreciated.

Best,  
Thomas